Literature DB >> 22078910

Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids.

John W Devlin1, Russel J Roberts.   

Abstract

The ideal sedative or analgesic agent should have a rapid onset of activity, a rapid recovery after drug discontinuation, a predictable dose response, a lack of drug accumulation,and no toxicity. Unfortunately, none of the earlier analgesics, the benzodiazepines,or propofol share all of these characteristics. Patients who are critically ill experience numerous physiologic derangements and commonly require high doses and long durations of analgesic and sedative therapy. There is a paucity of well designed clinical trials evaluating the safety and efficacy of earlier sedative and analgesic agents in the ICU. In addition, the ever-changing dynamics of patients who are critically ill makes the use of sedation a continual challenge during the course of each patient’s admission. To optimize care, clinicians should be familiar with the many pharmacokinetic, pharmacodynamic, and pharmacogenetic variables that can affect the safety and efficacy of sedatives and analgesics.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID: 22078910     DOI: 10.1016/j.anclin.2011.09.001

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  16 in total

1.  Review on sedation for gastrointestinal tract endoscopy in children by non-anesthesiologists.

Authors:  Rok Orel; Jernej Brecelj; Jorge Amil Dias; Claudio Romano; Fernanda Barros; Mike Thomson; Yvan Vandenplas
Journal:  World J Gastrointest Endosc       Date:  2015-07-25

2.  Benzodiazepine-associated delirium in critically ill adults.

Authors:  Irene J Zaal; John W Devlin; Marijn Hazelbag; Peter M C Klein Klouwenberg; Arendina W van der Kooi; David S Y Ong; Olaf L Cremer; Rolf H Groenwold; Arjen J C Slooter
Journal:  Intensive Care Med       Date:  2015-09-24       Impact factor: 17.440

3.  Risk factors for ventilator-associated events: a case-control multivariable analysis.

Authors:  Sarah C Lewis; Lingling Li; Michael V Murphy; Michael Klompas
Journal:  Crit Care Med       Date:  2014-08       Impact factor: 7.598

4.  High-performance liquid chromatographic determination of propofol in human plasma: comparison of different heteroscedastic calibration curve models.

Authors:  Pooria Taghavi Moghaddam; Mohammad Reza Pipelzadeh; Sholeh Nesioonpour; Nader Saki; Saeed Rezaee
Journal:  Adv Pharm Bull       Date:  2014-08-10

Review 5.  Considerations for analgosedation and antithrombotic management during extracorporeal life support.

Authors:  Pamela K Burcham; Alan J Rozycki; Erik E Abel
Journal:  Ann Transl Med       Date:  2017-02

Review 6.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

7.  Persistence of Delirium after Cessation of Sedatives and Analgesics and Impact on Clinical Outcomes in Critically Ill Patients.

Authors:  Michael T Kenes; Joanna L Stollings; Li Wang; Timothy D Girard; E Wesley Ely; Pratik P Pandharipande
Journal:  Pharmacotherapy       Date:  2017-10-17       Impact factor: 4.705

8.  Malignant cerebellar edema in three-year-old girl following accidental opioid ingestion and fentanyl administration.

Authors:  Cathy H Chen; Alexander J Mullen; Dustin Hofstede; Tanvir Rizvi
Journal:  Neuroradiol J       Date:  2019-07-22

9.  Comparison of dexmedetomidine, propofol and midazolam for short-term sedation in postoperatively mechanically ventilated neurosurgical patients.

Authors:  Vinit K Srivastava; Sanjay Agrawal; Sanjay Kumar; Abhishek Mishra; Sunil Sharma; Raj Kumar
Journal:  J Clin Diagn Res       Date:  2014-09-20

10.  Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers.

Authors:  P Uusalo; D Al-Ramahi; I Tilli; R A Aantaa; M Scheinin; T I Saari
Journal:  Eur J Clin Pharmacol       Date:  2018-04-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.